Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease

Aβ plaque formation is a prominent cellular hallmark of Alzheimer’s disease (AD). To date, immunization trials in AD patients have not been effective in terms of curing or ameliorating dementia. In addition, γ-secretase inhibitor strategies await clinical improvements in AD. These approaches were ba...

Full description

Bibliographic Details
Main Authors: Romina Jozefa Gentier, Fred W. Van eLeeuwen
Format: Article
Language:English
Published: Frontiers Media S.A. 2015-09-01
Series:Frontiers in Molecular Neuroscience
Subjects:
Online Access:http://journal.frontiersin.org/Journal/10.3389/fnmol.2015.00047/full
_version_ 1811255799082647552
author Romina Jozefa Gentier
Fred W. Van eLeeuwen
author_facet Romina Jozefa Gentier
Fred W. Van eLeeuwen
author_sort Romina Jozefa Gentier
collection DOAJ
description Aβ plaque formation is a prominent cellular hallmark of Alzheimer’s disease (AD). To date, immunization trials in AD patients have not been effective in terms of curing or ameliorating dementia. In addition, γ-secretase inhibitor strategies await clinical improvements in AD. These approaches were based upon the idea that autosomal dominant mutations in amyloid precursor protein and Presenilin 1 genes are predictive for treatment of all AD patients. However most AD patients are of the sporadic form which partly explains the failures to treat this multifactorial disease. The major risk factor for developing sporadic AD is aging whereas the ε4 polymorphism is the most prominent genetic risk factor. Other medium-risk factors such as TREM 2 and nine low risk factors from Genome Wide Association Studies (GWAS) were associated with AD. Recently, pooled GWAS studies identified protein ubiquitination as one of the key modulators of AD. In addition, a brain site specific strategy was used to compare the proteomes of AD patients by an Ingenuity Pathway Analysis. This strategy revealed numerous proteins that strongly interact with ubiquitin signaling, and pointing to a dysfunctional ubiquitin proteasome system (UPS) as a causal factor in AD. We reported that DNA-RNA sequence differences in several genes including ubiquitin do occur in AD, the resulting misframed protein of which accumulates in the cellular hallmarks of AD. This suggests again a functional link between neurodegeneration of the AD type and loss of protein quality control by the UPS. Progress in this field is discussed and modulating the activity of the UPS opens an attractive avenue of research towards slowing down the development of AD and ameliorating its effects by discovering prime targets for AD therapeutics.
first_indexed 2024-04-12T17:30:31Z
format Article
id doaj.art-c2bed478f0f145e88aa765ec3e3a0c25
institution Directory Open Access Journal
issn 1662-5099
language English
last_indexed 2024-04-12T17:30:31Z
publishDate 2015-09-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Molecular Neuroscience
spelling doaj.art-c2bed478f0f145e88aa765ec3e3a0c252022-12-22T03:23:09ZengFrontiers Media S.A.Frontiers in Molecular Neuroscience1662-50992015-09-01810.3389/fnmol.2015.00047156720Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s diseaseRomina Jozefa Gentier0Fred W. Van eLeeuwen1Maastricht UniversityMaastricht UniversityAβ plaque formation is a prominent cellular hallmark of Alzheimer’s disease (AD). To date, immunization trials in AD patients have not been effective in terms of curing or ameliorating dementia. In addition, γ-secretase inhibitor strategies await clinical improvements in AD. These approaches were based upon the idea that autosomal dominant mutations in amyloid precursor protein and Presenilin 1 genes are predictive for treatment of all AD patients. However most AD patients are of the sporadic form which partly explains the failures to treat this multifactorial disease. The major risk factor for developing sporadic AD is aging whereas the ε4 polymorphism is the most prominent genetic risk factor. Other medium-risk factors such as TREM 2 and nine low risk factors from Genome Wide Association Studies (GWAS) were associated with AD. Recently, pooled GWAS studies identified protein ubiquitination as one of the key modulators of AD. In addition, a brain site specific strategy was used to compare the proteomes of AD patients by an Ingenuity Pathway Analysis. This strategy revealed numerous proteins that strongly interact with ubiquitin signaling, and pointing to a dysfunctional ubiquitin proteasome system (UPS) as a causal factor in AD. We reported that DNA-RNA sequence differences in several genes including ubiquitin do occur in AD, the resulting misframed protein of which accumulates in the cellular hallmarks of AD. This suggests again a functional link between neurodegeneration of the AD type and loss of protein quality control by the UPS. Progress in this field is discussed and modulating the activity of the UPS opens an attractive avenue of research towards slowing down the development of AD and ameliorating its effects by discovering prime targets for AD therapeutics.http://journal.frontiersin.org/Journal/10.3389/fnmol.2015.00047/fulltau Proteinsneurodegenerationamyloid precursor proteinProteasomemRNA surveillanceframeshift mutation
spellingShingle Romina Jozefa Gentier
Fred W. Van eLeeuwen
Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease
Frontiers in Molecular Neuroscience
tau Proteins
neurodegeneration
amyloid precursor protein
Proteasome
mRNA surveillance
frameshift mutation
title Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease
title_full Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease
title_fullStr Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease
title_full_unstemmed Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease
title_short Misframed ubiquitin and impaired protein quality control; an early event in Alzheimer’s disease
title_sort misframed ubiquitin and impaired protein quality control an early event in alzheimer s disease
topic tau Proteins
neurodegeneration
amyloid precursor protein
Proteasome
mRNA surveillance
frameshift mutation
url http://journal.frontiersin.org/Journal/10.3389/fnmol.2015.00047/full
work_keys_str_mv AT rominajozefagentier misframedubiquitinandimpairedproteinqualitycontrolanearlyeventinalzheimersdisease
AT fredwvaneleeuwen misframedubiquitinandimpairedproteinqualitycontrolanearlyeventinalzheimersdisease